Oxygenta Pharmaceutical Limited (BOM:524636)
India · Delayed Price · Currency is INR 58.00
+1.00 (1.75%)
At close: Jan 22, 2026
Oxygenta Pharmaceutical Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 1,121 | 1,093 | 396.42 | 309.88 | 605.25 | 520.27 | Upgrade |
Other Revenue | 0 | - | - | -0 | 0 | - | Upgrade |
| 1,121 | 1,093 | 396.42 | 309.87 | 605.25 | 520.27 | Upgrade | |
Revenue Growth (YoY) | 141.99% | 175.71% | 27.93% | -48.80% | 16.33% | 279.03% | Upgrade |
Cost of Revenue | 1,168 | 1,071 | 405.89 | 300.79 | 564.29 | 422.99 | Upgrade |
Gross Profit | -47.04 | 21.86 | -9.47 | 9.08 | 40.96 | 97.28 | Upgrade |
Selling, General & Admin | 82.12 | 70.52 | 61.74 | 60.42 | 7.87 | 42.64 | Upgrade |
Other Operating Expenses | 40.67 | 46.67 | 25.65 | 19.83 | 18.33 | 16.22 | Upgrade |
Operating Expenses | 134.9 | 125.35 | 113.99 | 100.77 | 42.12 | 70.82 | Upgrade |
Operating Income | -181.94 | -103.5 | -123.46 | -91.69 | -1.15 | 26.47 | Upgrade |
Interest Expense | -24.97 | -20.17 | -15.81 | -14.75 | -9.15 | -17.75 | Upgrade |
Interest & Investment Income | 0.23 | 0.23 | 0.18 | 0.05 | 0.04 | 0.23 | Upgrade |
Currency Exchange Gain (Loss) | -1.59 | -1.59 | 0.14 | 0.13 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 5.62 | 12.21 | -0.13 | -0.13 | -0.1 | 0.61 | Upgrade |
EBT Excluding Unusual Items | -202.66 | -112.82 | -139.09 | -106.38 | -10.36 | 9.55 | Upgrade |
Gain (Loss) on Sale of Assets | 0.49 | 0.49 | - | - | - | - | Upgrade |
Other Unusual Items | -3.34 | -3.2 | 0.37 | -7.34 | 5.46 | 21.89 | Upgrade |
Pretax Income | -205.51 | -115.53 | -138.72 | -113.73 | -4.89 | 31.44 | Upgrade |
Income Tax Expense | -40.46 | -18.7 | -103.92 | 1.98 | 1.21 | 2.14 | Upgrade |
Net Income | -165.04 | -96.83 | -34.79 | -115.71 | -6.1 | 29.3 | Upgrade |
Net Income to Common | -165.04 | -96.83 | -34.79 | -115.71 | -6.1 | 29.3 | Upgrade |
Shares Outstanding (Basic) | 37 | 36 | 32 | 14 | 13 | 10 | Upgrade |
Shares Outstanding (Diluted) | 37 | 36 | 32 | 14 | 13 | 13 | Upgrade |
Shares Change (YoY) | 7.58% | 12.20% | 125.61% | 11.43% | - | 24.84% | Upgrade |
EPS (Basic) | -4.47 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | Upgrade |
EPS (Diluted) | -4.47 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | Upgrade |
Free Cash Flow | -112.13 | -87.89 | -171.55 | -112.79 | -66.26 | -83.63 | Upgrade |
Free Cash Flow Per Share | -3.04 | -2.44 | -5.35 | -7.94 | -5.20 | -6.56 | Upgrade |
Gross Margin | -4.20% | 2.00% | -2.39% | 2.93% | 6.77% | 18.70% | Upgrade |
Operating Margin | -16.23% | -9.47% | -31.14% | -29.59% | -0.19% | 5.09% | Upgrade |
Profit Margin | -14.72% | -8.86% | -8.78% | -37.34% | -1.01% | 5.63% | Upgrade |
Free Cash Flow Margin | -10.00% | -8.04% | -43.28% | -36.40% | -10.95% | -16.07% | Upgrade |
EBITDA | -169.83 | -95.34 | -96.85 | -71.17 | 14.76 | 38.42 | Upgrade |
EBITDA Margin | -15.15% | -8.72% | -24.43% | -22.97% | 2.44% | 7.39% | Upgrade |
D&A For EBITDA | 12.11 | 8.16 | 26.61 | 20.52 | 15.91 | 11.96 | Upgrade |
EBIT | -181.94 | -103.5 | -123.46 | -91.69 | -1.15 | 26.47 | Upgrade |
EBIT Margin | -16.23% | -9.47% | -31.14% | -29.59% | -0.19% | 5.09% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 6.81% | Upgrade |
Revenue as Reported | 1,128 | 1,106 | 396.85 | 310.05 | 605.29 | 521.18 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.